secwatch.observer — SEC 8-K summary
======================================

Issuer:     Corvus Pharmaceuticals, Inc. (CRVS)
CIK:        0001626971
Form:       8-K
Filed at:   2025-10-02T23:59:59+00:00
Accession:  0001104659-25-096103
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

David Moore joins Corvus board as Class III director through 2028; gets 30K option grant
--------------------------------------------------------------------------------

- David Moore appointed as Class III director, term expires at 2028 annual meeting.
- Moore will serve on Compensation Committee ($6K/yr) and Nominating Committee ($4K/yr).
- Receives $35K annual retainer and initial option to purchase 30,000 shares of common stock.
- Appointment effective October 2, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1626971/000110465925096103/0001104659-25-096103-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1626971/000110465925096103/crvs-20251002x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-096103

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer